An Update on ISoP Special Interest Groups (SIGs)
Drug Saf
.
2018 Jan;41(1):1-6.
doi: 10.1007/s40264-017-0603-5.
Authors
Deirdre McCarthy
1
,
Priya Bahri
2
,
Joanne Barnes
3
,
Jean-Christophe Delumeau
4
,
Brian Edwards
5
,
Mira Harrison-Woolrych
6
Affiliations
1
Lifecycle Safety, QuintilesIMS, Cambridge, MA, USA. deemccarthy1234@gmail.com.
2
Pharmacovigilance and Epidemiology Department, European Medicines Agency (EMA), London, UK.
3
School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
4
Head of Pharmacovigilance Policy Strategy (Global), Bayer (South East Asia) Pte Ltd., OCBC Centre East, 63 Chulia Street, Singapore, Singapore.
5
NDA Regulatory Science Ltd, Leatherhead, UK.
6
Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
PMID:
28980202
DOI:
10.1007/s40264-017-0603-5
No abstract available
Publication types
Editorial
MeSH terms
Humans
International Cooperation
Pharmacovigilance*
Public Opinion*
Societies, Pharmaceutical*